» Articles » PMID: 14960659

68Ga-labeled Oligonucleotides for in Vivo Imaging with PET

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2004 Feb 13
PMID 14960659
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: The biologic evaluation in living rats of (68)Ga-labeled oligonucleotides as imaging agents for PET is reported.

Methods: (68)Ga, a positron-emitting radionuclide (half-life, 68 min), along with a macrocyclic chelating agent, 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA), was used for labeling of antisense oligonucleotides targeting activated human K-ras oncogene. The biologic properties of 3 different forms of the oligonucleotides-that is, 2'-deoxyphosphodiester (PO), 2'-deoxyphosphorothioate (PS), and 2'-O-methyl phosphodiester (OMe)-were studied first. The biodistribution and biokinetics were evaluated in vivo in athymic rats, each bearing a tumor of A549 cells, containing K-ras point mutation in codon 12, and a tumor of BxPC-3 cells, containing wild-type K-ras. Dynamic PET imaging lasting up to 2 h was performed immediately after intravenous injection of (68)Ga-oligonucleotide. Blank studies were performed using (68)GaCl(3) or (68)Ga-DOTA alone without oligonucleotide. The (68)Ga-antisense oligonucleotide uptake in tumors was also compared with the (18)F-FDG and (68)Ga-sense oligonucleotide uptakes. In addition, oligonucleotide binding to human plasma proteins and to human albumin was examined by means of ultrafiltration.

Results: The oligonucleotides can be stably labeled with (68)Ga and DOTA chelate. Intravenously injected (68)Ga-oligonucleotides of 17-mer length revealed high-quality PET images, allowing quantification of the biokinetics in major organs and in tumors. The biodistribution and biokinetics of intravenously administered (68)Ga-oligonucleotide varied considerably with the nature of the oligonucleotide backbone.

Conclusion: We conclude that (68)Ga labeling of oligonucleotides is a convenient approach for in vivo imaging and quantification of oligonucleotide biokinetics in living animals with PET.

Citing Articles

Imaging-Assisted Antisense Oligonucleotide Delivery for Tumor-Targeted Gene Therapy.

Liao H, Wang S, Wang X, Dai D, Zhang Y, Zhu C Chem Biomed Imaging. 2024; 2(5):313-330.

PMID: 39474120 PMC: 11503958. DOI: 10.1021/cbmi.4c00012.


RNA nanostructures for targeted drug delivery and imaging.

Teodori L, Omer M, Kjems J RNA Biol. 2024; 21(1):1-19.

PMID: 38555519 PMC: 10984137. DOI: 10.1080/15476286.2024.2328440.


In vivo tissue pharmacokinetics of ERBB2-specific binding oligonucleotide-based drugs by PET imaging.

Park S, Baek S, Lee J, Woo S, Lee T, Park H Clin Transl Sci. 2023; 16(7):1186-1196.

PMID: 37038354 PMC: 10339696. DOI: 10.1111/cts.13522.


Preparation and SPECT/CT Imaging of Lu-Labeled Peptide Nucleic Acid (PNA) Targeting CITED1: Therapeutic Evaluation in Tumor-Bearing Nude Mice.

Li J, Zhang L, Li W, Lei C, Cao Y, Wang Y Onco Targets Ther. 2020; 13:487-496.

PMID: 32021292 PMC: 6970276. DOI: 10.2147/OTT.S238098.


Research Progress of [Ga]Citrate PET's Utility in Infection and Inflammation Imaging: a Review.

Xu T, Chen Y Mol Imaging Biol. 2019; 22(1):22-32.

PMID: 31076971 DOI: 10.1007/s11307-019-01366-x.